Posted inInteresting Papers
Checkpoint Inhibitors and Ocular Side Effects
Overview of Checkpoint Inhibitors: Checkpoint inhibitors are humanized monoclonal antibodies that activate T-cells to target tumor cell antigens, first FDA-approved in 2011. Common agents: pembrolizumab, ipilimumab, nivolumab (recognizable by “-mab”…







